STUDI PENGGUNAAN OBAT ANTIEMETIK SEBAGAI PREMEDIKASI KEMOTERAPI PADA PASIEN KANKER PAYUDARA (Penelitian di RSU Dr. Soetomo Surabaya)

HERDWIANTI KARTIKASARI, 050710196 (2012) STUDI PENGGUNAAN OBAT ANTIEMETIK SEBAGAI PREMEDIKASI KEMOTERAPI PADA PASIEN KANKER PAYUDARA (Penelitian di RSU Dr. Soetomo Surabaya). Skripsi thesis, UNIVERSITAS AIRLANGGA.

[img]
Preview
Text (ABSTRAK)
ABSTRAK.pdf

Download (262kB) | Preview
[img] Text (FULLTEXT)
download.php_id=gdlhub-gdl-s1-2012-herdwianti-18774&no=1
Restricted to Registered users only

Download (1kB) | Request a copy
Official URL: http://lib.unair.ac.id

Abstract

Breast cancer is a disease that most commonly occurring cancer in women, ranked second after cervical cancer. Chemotherapy has been integrated in the package of breast cancer treatment. Unfortunately, nausea and vomiting are two of the most side effects of chemotherapy. Therefore, its important to know the pattern of antiemetic drugs use as premedication chemotherapy in breast cancer patients (including type, dose, frequency, route and DRP). The purpose of this study is to examine patterns of drug use as an antiemetic premedication efforts in breast cancer patients undergoing chemotherapy in RSU Dr. Soetomo Surabaya and identify the presence of DRP (Drug Related Problems) that may occur. Research carried out is an observational study and analyzed descriptively. Data was collected prospectively, by following the pattern of patient therapy that is being undertaken during the given period. The research was conducted in 35 breast cancer patients who underwent outpatient in POSA (Poli Onkologi Satu Atap) RSU Dr. Surabaya Soetomo period April 28th 2011 until June 3th 2011. The results showed that 34 patients receiving moderate emetogenic chemotherapy, namely the CAF, CEF, CAV and CE. While one patients received drug with highly emetogenic chemotherapy (paklitaksel-cisplatin). Effort to premedication, all patients received the same antiemetic (type, dose, frequency, and route of administration), namely ondansetron (16 mg), dexamethasone (20 mg), diphenhydramine (10 mg) and ranitidine (50 mg) intravenously at 1 hour prior to chemotherapy. Of the 35 patients, 29 patients experienced side effects nausea vomiting (26 patients experienced nausea vomiting, delayed type). Drug Related Problems/DRP which arises is the potential for drug interactions. While the suitability of antiemetic drug doses used based on literature studies. In this study, it is advisable to do patient assessments to determine risk factors for CINV are owned by the patient because it can help physicians and pharmacists to determine the appropriate antiemetic drugs resulting in optimal prevention of CINV.

Item Type: Thesis (Skripsi)
Additional Information: KKB KK-2 FF 334 / 11 Kar s
Uncontrolled Keywords: CHEMOTHERAPY
Subjects: R Medicine > RM Therapeutics. Pharmacology
R Medicine > RM Therapeutics. Pharmacology > RM260-263 Chemotherapy
Divisions: 05. Fakultas Farmasi
Creators:
CreatorsEmail
HERDWIANTI KARTIKASARI, 050710196UNSPECIFIED
Contributors:
ContributionNameEmail
ContributorBambang Subakti Z, .S.Si.M.Clin.Pharm.,Ap tUNSPECIFIED
Depositing User: Mr Mudjiono Mudj
Date Deposited: 27 Jan 2012 12:00
Last Modified: 12 Aug 2016 03:08
URI: http://repository.unair.ac.id/id/eprint/8966
Sosial Share:

Actions (login required)

View Item View Item